Biotech Values

[bladerunner1717]

How does the CEO change at MVOV affect your buyout thesis?

This is just speculation from a not-very-bright-biotech investor. The way I see it, Marek is Sumitomo's guy. The buyout of MYOV will just go a whole lot smoother--psychologically as well as financially--if you don't have a medical/science person at the helm. (Sumitomo doesn't need that.) Marek can more easily fit into a Sumitomo corporate structure that a Lynn Seeley type. And his knowledge of Internet marketing may be something that Sumitomo can use.

If this is just a straight-up kind of deal for a new biotech CEO, then I think Marek is a terrible choice.

So, to directly answer your question, I think Marek is there to facilitate a Sumitomo buyout. I think Mr. Market doesn't understand this. Mr. Market just sees this as a lousy choice for a small-cap biotech CEO.

Bladerunner